• Kimball Electronics expects organic growth in fiscal 2027 as it expands its medical contract development and manufacturing business.
• The acquisition of Helvoet Polymer Technologies is expected to increase earnings, adding medical manufacturing capabilities in Europe and India.
• A new Indianapolis manufacturing facility doubles its footprint for producing medical products, surgical instruments and drug delivery devices.
• Improved capacity utilization is expected to lift margins, supported by a rising medical revenue share.
• Short-term liquidity totaled $271 million as of September 30, 2026, providing capacity to invest in growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kimball Electronics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.